Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Predictors and Outcomes of Amyloid Cardiomyopathy caused by Transthyretin V30 Mutation
Session:
SESSÃO DE POSTERS 26 - CARDIOGENÉTICA EM AÇÃO!
Speaker:
Mariana Pereira Fernandes dos Santos
Congress:
CPC 2025
Topic:
K. Cardiovascular Disease In Special Populations
Theme:
30. Cardiovascular Disease in Special Populations
Subtheme:
30.10 Neurologic Disorders and Heart Disease
Session Type:
Cartazes
FP Number:
---
Authors:
Mariana Pereira Santos; Alexandra Pinto Pires; David Sá Couto; Diana Ribeiro; Pedro Monteiro; Tiago Peixoto; Andreia Campinas; Marta Fontes Oliveira; Sara Fernandes; Hipólito Reis; Severo Torres; Patrícia Rodrigues
Abstract
<p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt"><strong>Background:</strong> Transthyretin-related amyloid cardiomyopathy (ATTR-CM) results from mutations in the TTR gene (vATTR) or conformational changes in wild-type TTR protein (wtATTR). Regarding TTR mutations, a particular early-onset phenotype, presenting predominantly as a peripheral neuropathy (named Familial Amyloid Polyneuropathy) is endemic in Portugal, with the V30M being the most common pathogenic variant. The aim of this study was to characterize the occurrence of V30M ATTR-CM, as well as its predictors and outcomes.</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt"><strong>Methods:</strong> We conducted a retrospective study including patients diagnosed with TTR V30M mutation, with and without amyloid cardiomyopathy, consequently seen in Cardiology appointments in 2019 at our center and followed for at least 5 years. Diagnostic criteria for ATTR-CM were considered according to ESC recommendations. Multiple linear regression was used to identify independent predictors for ATTR-CM. Death rates were plotted as Kaplan-Meier curves. </span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt"><strong>Results:</strong> We enrolled a total of 248 TTR V30M patients, mean age of 54 years old, 53% males, 68% with early onset disease (<50 years); 49 (21%) patients fulfilled the criteria for ATTR-CM diagnosis (with an additional 10% possibly having cardiomyopathy without fulfilling all diagnostic criteria).</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt"> V30M ATTR-CM was associated with male gender (78% vs 46%, p<0.001), older age (62.4±13.7 years vs 52.1±13.4 years, p<0.001), late-onset disease (40% vs 18%, p=0.002), liver transplantation (49% vs 28%, p=0.004), orthostatic hypotension (55% vs 30%, p<0.001), ophthalmologic manifestations (31% vs 16%, p=0.019), and lower creatinine clearance (81.5±25.3 ml/min vs 94.0±30.4 ml/min, p=0.009). There was no difference between groups regarding neurological involvement (present in 90% vs 82%) or GI, renal and urological manifestations.</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt">In multivariate analysis, male gender (OR 4,69; 95% CI 1.85–11.93; p<0.001) and liver transplant (OR 6.41; 95% CI 1.93–21.24; p=0.002) were the only independent predictors of CM identified.</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt">Median follow-up time was 57 (5) months. ATTR-CM was associated with worse outcomes (survival 78.5% vs 91.3%, LogRank = 0.034) (Figure 1). </span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:11pt"><strong>Conclusion</strong>: ATTR-CM affects more than one fifth of our TTR V30M patients and is independently predicted by male gender and liver transplantation. It is associated with worse outcomes, highlighting the need for early detection and management to improve prognosis.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site